Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone Marrow-Derived MSC Therapy for Chronic Kidney Disease
NCT05362786Phase 1Completed
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic bone marrow-derived mesenchymal stromal cells in chronic kidney disease (CKD) (2 arms). Primary endpoints: Adverse events and/or serious adverse events at 15 months and Change in eGFR Value at 6 months. Started Jul 2022; status: completed.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05362786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362786.